In addition, a study in 2014 showed that luminal B patients (either HER2+ or HER2-) had a strong relationship with node involvement, and that triple positive and triple negative breast cancer exhibited the highest and lowest probability of axillary lymph node involvement, respectively (Si et al., 2014). Here, ERBB2 is linked to triple-negative breast carcinoma.